@Boffin99
It's a very average evaluation of value and potential.
32% chance of success for a drug that leads single-agent efficacy and is comparable to combinations in R/R AML with a differentiated first-in-class mechanism of action in FTO inhibition.
For those with the motivation to look, there is an enormous amount of data out there supporting FTO inhibition and CPACS. For a potent example, of 4 patients who were refractory to two courses of combination antimetabolites, 3 achieved durable complete responses (75%) after a single 7-day dose of Bisantrene.
40-years later the mechanism of Ara-C resistance, and sensitivity to Bisantrene may be understood.
@hotcongo probably the company that owns the IP to the reformulation of Bisantrene with a 20-year patent life. Seriously.
- Forums
- ASX - By Stock
- Ann: Race In-person Investor Briefing Invitation Perth
@Boffin99It's a very average evaluation of value and potential....
-
- There are more pages in this discussion • 110 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.78 |
Change
-0.040(2.20%) |
Mkt cap ! $302.5M |
Open | High | Low | Value | Volume |
$1.81 | $1.82 | $1.76 | $132.8K | 74.40K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 170 | $1.77 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.78 | 2 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 4000 | 1.755 |
3 | 12714 | 1.750 |
1 | 3000 | 1.740 |
1 | 1405 | 1.720 |
4 | 25414 | 1.700 |
Price($) | Vol. | No. |
---|---|---|
1.780 | 3781 | 1 |
1.830 | 7500 | 1 |
1.840 | 1000 | 1 |
1.850 | 5222 | 1 |
1.880 | 2351 | 1 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |